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Patrick Schöffski, MD, MPH19; Matteo S. Carlino, BMedSc, MBBS, PhD20; Céleste Lebbé, MD, PhD21; Grant McArthur, MD, PhD22;
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abstract
PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with
nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and
safety outcomes.
PATIENTS AND METHODS Patients with previously untreated unresectable stage III or stage IV melanoma were
randomly assigned 1:1:1 to receive nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks (four
doses) followed by nivolumab 3 mg/kg once every 2 weeks (n 5 314), nivolumab 3 mg/kg once every 2 weeks
(n 5 316), or ipilimumab 3 mg/kg once every 3 weeks (four doses; n 5 315). Coprimary end points were
progression-free survival and overall survival (OS) with nivolumab plus ipilimumab or nivolumab versus ipili-
mumab. Secondary end points included objective response rate, descriptive efficacy assessments of nivolumab
plus ipilimumab versus nivolumab alone, and safety. Melanoma-specific survival (MSS; descriptive analysis),
which excludes deaths unrelated to melanoma, was also evaluated.
RESULTS Median OS (minimum follow-up, 6.5 years) was 72.1, 36.9, and 19.9 months in the combination,
nivolumab, and ipilimumab groups, respectively.MedianMSSwas not reached, 58.7, and21.9 months, respectively;
6.5-year OS rates were 57%, 43%, and 25% in patients withBRAF-mutant tumors and 46%, 42%, and 22% in those
withBRAF–wild-type tumors, respectively. In patients who discontinued treatment, themedian treatment-free interval
was 27.6, 2.3, and 1.9 months, respectively. Since the 5-year analysis, no new safety signals were observed.
CONCLUSION These 6.5-year CheckMate 067 results, which include the longest median OS in a phase III
melanoma trial reported to date and the first report of MSS, showed durable, improved clinical outcomes with
nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in
descriptive analyses, with the combination over nivolumab monotherapy.
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INTRODUCTION
The development of immune checkpoint inhibitors
and BRAF- and MEK-targeted therapies has led to a
transformation of survival outcomes in patients with
advanced melanoma.1 In particular, the programmed
cell death 1 inhibitors nivolumab and pembrolizumab
and the cytotoxic T-lymphocyte–associated protein-4
blocking antibody ipilimumab have reshaped immu-
nologic approaches to the treatment of this disease.
Evidence from the randomized controlled, double-blind
phase II CheckMate 069 and phase III CheckMate 067
trials established the combination of nivolumab and
ipilimumab as a standard care option for patients with
metastatic melanoma.2-7
A 5-year follow-up analysis of the CheckMate 067 trial
demonstrated durable clinical benefit with nivolumab
plus ipilimumab or nivolumab alone compared with
ipilimumab monotherapy.7 At 5 years, median overall
survival (OS) was not reached in patients in the
combination therapy group and was 36.9 and
19.9 months in the nivolumab and ipilimumab mon-
otherapy groups, respectively. Five-year OS rates were
52%, 44%, and 26% in the three groups, respectively,
and among patients with BRAF-mutant advanced
melanoma, 5-year OS rates were 60%, 46%, and
30%, respectively. Noting that the study was not
designed to compare the nivolumab-containing
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improved clinical outcomes with combination therapy over
nivolumab monotherapy. Compared with either mono-
therapy group, treatment with the combination also
resulted in higher proportions of patients who were alive
and treatment-free at 5 years. Little is known about the
long-term outcomes of nivolumab plus ipilimumab or
nivolumab alone in melanoma beyond 5 years. In the
current report, we describe an analysis of efficacy and
safety in CheckMate 067 at 6.5 years of follow-up, which is
the longest follow-up of a phase III trial with an anti-
programmed cell death 1–based treatment in melanoma.
In addition to reporting updates on long-term survival and
safety, our analysis included melanoma-specific survival
(MSS), which is increasingly valuable in removing the non–
disease-related deaths that become an increasingly im-
portant consideration with long-term follow-up.
PATIENTS AND METHODS
Patients
Eligible adult patients had previously untreated and
unresectable or metastatic histologically confirmed stage III
or stage IV melanoma with known BRAF V600 mutation
status and an Eastern Cooperative Oncology Group per-
formance status of 0 or 1. Trial eligibility criteria have been
described in detail previously.4-6 All patients provided
written informed consent.
Study Design, Treatment, and Assessments
The design of this trial and the assessments used have been
detailed previously.4-6 In brief, patients were randomly as-
signed (1:1:1) to receive nivolumab 1 mg/kg plus ipilimumab
3 mg/kg once every 3 weeks for four doses, followed by
nivolumab 3 mg/kg once every 2 weeks; nivolumab 3 mg/kg
once every 2 weeks; or ipilimumab 3 mg/kg once every
3 weeks for four doses. All treatment regimens were
appropriately placebo-matched for the purposes of blinding.
Stratification factors were BRAF mutation status, American
Joint Committee on Cancer (seventh edition) metastasis
stage, and tumor programmed cell death ligand 1 status.
Treatment was discontinued in the event of progressive
disease (PD), the occurrence of unacceptable toxic events,
or withdrawal of consent. Treatment could be continued
beyond PD on the basis of clinical benefit without substantial
adverse events (AEs) per investigator decision.
Progression-free survival (PFS; investigator-assessed) and
OS in the combination or the nivolumab group compared
with the ipilimumab group were coprimary end points.
Secondary end points included comparison of investigator-
assessed objective response rates (ORRs) in the
nivolumab-containing groups and the ipilimumab group,
comparison of efficacy in the combination and the
nivolumab groups (descriptive analyses), and safety. MSS
(which excludes deaths unrelated to melanoma) and
survival outcomes by best overall response were descriptive
post hoc analyses. AEs were defined using the Medical
Dictionary for Regulatory Activities version 23.0 and graded
on the basis of Common Terminology Criteria for Adverse
Events version 4.0. Immune-mediated AEs, defined as
events for which immune-modulating medication was ini-
tiated (except for endocrine events, which did not require
immune-modulating medication initiation to be included),
and select AEs (defined as events with a potential immu-
nologic cause in the categories of skin, gastrointestinal,
hepatic, pulmonary, renal, hypersensitivity or infusion re-
action, or endocrine) were evaluated. Additional exploratory
analyses (survival outcomes in other subgroups, treatment-
free interval [TFI; the time from the last dose of study drug to
subsequent systemic therapy initiation or the last known
date alive, excluding patients who had discontinued study
follow-up or had died before receiving subsequent systemic
CONTEXT
Key Objective
Long-term survival of patients with advanced melanoma treated with nivolumab plus ipilimumab and nivolumab alone
versus ipilimumab has been demonstrated after 5-year follow-up in the phase III CheckMate 067 trial. The extent of the
durability of this benefit is of interest. We present 6.5-year results from CheckMate 067, including a first report of
melanoma-specific survival.
Knowledge Generated
Prolonged survival can be attained in patients with melanoma treated with nivolumab plus ipilimumab or nivolumab alone
with median overall survival of 72.1 and 36.9 months, and median melanoma-specific survival not reached and 58.7
months, respectively. The majority of these patients are off treatment and have not yet started systemic subsequent
therapy.
Relevance
These results represent a substantial development in the melanoma treatment landscape versus the standard median
survival of 8 months a decade ago. This advance is supported by the ability to distinguish melanoma-specific from overall
survival.
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therapy], and treatment-free status) have been described
previously.5,6
The trial was conducted in accordance with the Declaration
of Helsinki and with Good Clinical Practice as defined by
the International Conference on Harmonisation. The study
was conducted in compliance with the Protocol (online
only), which was approved by each study center’s insti-
tutional review board.
Statistical Analysis
Efficacy end points were analyzed in the intent-to-treat
population, and formal analysis of the coprimary end
points was conducted as reported previously.4,5 Updated
P values accompanying the current 6.5-year follow-up
assessments of PFS, OS, and ORR were descriptive in
nature. Updated rates accompanying assessments of PFS
and OS were included where the numbers of patients at risk
allowed. The study was not designed or powered for a
formal comparison between the nivolumab plus ipilimumab
and the nivolumab treatment groups. In a post hoc analysis
of MSS, events were defined as deaths because of mela-
noma; deaths because of other causes were censored.




Of the 1,296 patients enrolled between July 2013 and
March 2014, 945 were randomly assigned (314 to com-
bination therapy, 316 to nivolumab, and 315 to ipilimumab;
Fig 1). Patient characteristics were well balanced (Data
Supplement, online only), as previously reported.4-7 At the
time of the data cutoff on October 19, 2020, minimum
follow-up for the study was 77 months from the date of the
first dose of the last patient to be randomly assigned, and
median follow-up (defined as the median time between
the first dose and date of death or last known alive for each
patient) was 57.5, 36.0, and 18.6 months in the combi-
nation, nivolumab, and ipilimumab groups, respectively.
At the time of the data cutoff, most patients were off
therapy (15 patients were continuing treatment: seven in
the combination group and eight in the nivolumab group;
Fig 1).
Efficacy
At 77 months’ minimum follow-up, both PFS and OS were
longer in the nivolumab-containing treatment groups than
in the ipilimumab group. Median investigator-assessed PFS
(95% CI) was 11.5 months (8.7 to 19.3) in the combination
group, 6.9 months (5.1 to 10.2) in the nivolumab group,
and 2.9 months (2.8 to 3.2) in the ipilimumab group, with
6.5-year PFS rates of 34%, 29%, and 7%, respectively (Fig
2A). Median OS (95% CI) was 72.1 months (38.2 to not
reached [NR]) in the combination group, 36.9 months
(28.2 to 58.7) in the nivolumab group, and 19.9 months
(16.8 to 24.6) in the ipilimumab group, with 6.5-year OS
rates of 49%, 42%, and 23%, respectively (Fig 2B). In a
descriptive post hoc analysis, median MSS (defined as
death caused by melanoma, with deaths resulting from
other causes censored) was NR, 58.7, and 21.9 months in
the three groups, respectively; 6.5-year MSS rates were
56%, 48%, and 27%, respectively (Fig 3). The number and
causes of nonmelanoma deaths are shown in the Data
Supplement.
Between the previous 5-year analysis7 and the current data
cutoff, a total of 11 patients died, all for reasons considered
to be unrelated to treatment (Data Supplement). Of these
11 patients, three, three, and two died as a result of
melanoma (with PD having been detected before the 5-year
analysis) in the combination, nivolumab, and ipilimumab
groups, respectively. In addition, in the nivolumab group,
one patient each died from adenocarcinoma and gall-
bladder malignancy, and in the ipilimumab group, the
cause of one patient’s death was unknown.
Long-term PFS and OS were also evaluated in a variety of
clinically relevant patient subgroups. In patients with
BRAF-mutant tumors, 6-year PFS rates (low numbers of
patients at risk at 6.5 years precluded reporting 6.5-year
values) were 38%, 23%, and 9% with the combination,
nivolumab, and ipilimumab, respectively (Fig 4A); rates
were 34%, 31%, and 6% in patients with BRAF–wild-type
tumors, respectively (Fig 4B). OS rates at 6.5 years were
57%, 43%, and 25% in patients with BRAF-mutant tumors
(Fig 4C) and 46%, 42%, and 22% in patients with BRAF–
wild-type tumors, respectively (Fig 4D). Median OS was
NR, 45.5, and 24.6 months in patients with BRAF-mutant
tumors and 39.1, 34.4, and 18.5 months in patients with
BRAF–wild-type tumors, respectively. Survival outcomes in
patients with or without liver metastases at baseline are
shown in Figure 5. Although numbers of patients at risk in
these subgroups were small in some of the treatment groups,
PFS and OS trends suggested clinical benefit in the
nivolumab-containing treatment groups, particularly, the
combination-therapy group, compared with the ipilimumab
group regardless of baseline liver metastases. OS results at
6.5 years in patient subgroups on the basis of tumor pro-
grammed cell death ligand 1 expression level were con-
sistent with those reported previously (Data Supplement).5-7
ORRs at 6.5 years remained unchanged from the previous
analysis at 5 years,7 with rates of 58%, 45%, and 19% with
the combination, nivolumab, and ipilimumab, respectively
(Data Supplement). Median duration of response had not
been reached at 77 months in both nivolumab-containing
treatment groups and was 19.2 months in the ipilimumab
group. Among patients with PD, the central nervous system
was the site of initial progression in 14 of 155 patients (9%)
in the combination group, 19 of 184 patients (10%) in the
nivolumab group, and 28 of 235 patients (12%) in the
ipilimumab group (Data Supplement). Between the 5- and
6.5-year data cutoff, seven patients experienced PD
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(combination, n 5 3; nivolumab, n 5 3; and ipilimumab,
n 5 1). A post hoc 12-month landmark analysis (to reduce
guarantee-time bias8) evaluated PFS and OS by best overall
response (Data Supplement, Fig 6). In both nivolumab-
containing groups, high rates of PFS and OS were observed
in patients who had an objective response and were
progression-free or alive at 12 months, respectively.
As reported previously,7 a smaller proportion of patients in
the combination therapy group received subsequent sys-
temic therapy than did those in the nivolumab or ipilimumab
groups (36%, 49%, and 66%, respectively; Data Supple-
ment). Median (95% CI) time from random assignment to
start of subsequent systemic therapy was NR (59.6 to NR),
25.2 months (16.0 to 43.2), and 8.0 months (95% CI, 6.5 to
8.7) in the three groups, respectively. The median TFI (the
time from the last dose of study drug to initiation of sub-
sequent systemic therapy or the last known date alive) was
27.6, 2.3, and 1.9 months in the three groups, respectively
(Fig 7A). Among patients who were alive at the data cutoff,
77%, 69%, and 43% in the three groups were treatment-
free, respectively (off study treatment, without having re-
ceived any subsequent systemic therapy; Fig 7B).
Safety
As expected, no new safety signals were detected.
Updated treatment-related adverse events (TRAEs),
immune-mediated AEs, and select TRAE data, including
Patients randomly assigned (n = 945)
Continuing treatment (n = 7) Continuing treatment (n = 0)
Included in intent-to-treat analysis (n = 314) Included in intent-to-treat analysis (n = 315)
Patients enrolled (N = 1,296)
Continuing treatment (n = 8)
Included in intent-to-treat analysis (n = 316)
Patients did not continue             (n = 306)
      Disease progression                 (n = 91)
      Study drug toxicity                 (n = 139)
      Deaths                                          (n = 4)
      AEs                                             (n = 18)
      Patient request                          (n = 30)
      Withdrew consent                      (n = 3)
      Maximum clinical benefit        (n = 16)
      Poor or noncompliance             (n = 1)
      No longer meets study criteria (n = 1) 
      Other                                           (n = 3)
Received at least 1 treatment
(safety population; n = 313)
Assigned to nivolumab plus ipilimumab
   (intent-to-treat population; n = 314)
Did not receive treatment            (n = 1)
   No longer met study criteria    (n = 1)
Received at least 1 treatment
(safety population; n = 313)
Assigned to nivolumab alone
   (intent-to-treat population; n = 316)
Did not receive treatment             (n = 3)
     No longer met study criteria   (n = 1)
     Withdrew consent                    (n = 1)
     Request to discontinue study  (n = 1)
Received at least 1 treatment
(safety population; n = 311)
Assigned to ipilimumab alone
   (intent-to-treat population; n = 315)
Did not receive treatment             (n = 4)
       No longer met study criteria  (n = 2)
       Withdrew consent                   (n = 1)
       Disease progression               (n = 1)
Patients did not continue (n = 311)
    Disease progression     (n = 224)
    Study drug toxicity         (n = 52)
    Death                                 (n = 1)
    AEs                                     (n = 6)
    Patient request                (n = 13)
    Withdrew consent             (n = 1)
    Maximum clinical benefit (n = 4)
    Poor or noncompliance     (n= 1)
    Administrative reasonsa   (n = 6)
    Other                                  (n = 3)
Excluded                                             (n = 351)
     AEs                                                     (n = 7)
     Withdrew consent                           (n = 45)
     Deaths                                                (n = 5)
     Lost to follow-up                               (n = 1)
     Poor or non-compliance                   (n = 7)
     No longer met eligibility criteria  (n = 273)
     Other                                                (n = 13)
Patients did not continue     (n = 305)
      Disease progression       (n = 180)
      Study drug toxicity           (n = 49)
      Death                                    (n = 1)
      AEs                                       (n = 8)
      Patient request                  (n = 39)
      Withdrew consent               (n = 2)
      Lost to follow-up                 (n = 1)
      Maximum clinical benefit (n = 21)
      Poor or noncompliance       (n= 1)
      Other                                    (n = 3)
FIG 1. CONSORT diagram. AE, adverse event. aSince the 3-year analysis, patients were unmasked and seven patients discontinued from
maintenance nivolumab placebo (six for “administrative reasons” and one for “other reasons”; this latter patient is included within the three
patients in this group with a reason for treatment discontinuation as “other”).
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time to onset and resolution, are presented in the Data
Supplement.
DISCUSSION
These 6.5-year data with the combination of first-line
nivolumab plus ipilimumab in the pivotal CheckMate 067
study include the longest median OS (72.1 months) re-
ported to date in a phase III study of patients with advanced
melanoma. For the first time, we are also able to report MSS
in this population (median not reached at 77 months and
6.5-year rate of 56% with the combination), which is im-
portant, given the increasing competing risk of death from
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FIG 2. (A) PFS and (B) OS in patients who received nivolumab plus ipilimumab, nivolumab, or ipilimumab. Patients were followed for a minimum of 77
months. All rates are based on the current 6.5-year analysis; rates shown at earlier time points may differ slightly from those of previous reports. aDescriptive
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Nivolumab Plus
Ipilimumab
(n = 314) 
Nivolumab
(n = 316) 
Ipilimumab
(n = 315) 
Median (95% CI), months NR (71.9 to NR) 58.7 (35.9 to NR) 21.9 (18.1 to 27.4)
HR (95% CI) v ipilimumab 0.48 (0.39 to 0.60) 0.59 (0.48 to 0.73) —
HR (95% CI) v nivolumab 0.81 (0.64 to 1.03) — —
FIG 3. MSS in patients who received nivolumab plus ipilimumab, nivolumab, or ipilimumab. In this descriptive post hoc analysis, an event was
defined as death as a result of melanoma; deaths as a result of any other causes were censored. HR, hazard ratio; MSS, melanoma-specific survival;
NR, not reached.
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checkpoint inhibitors affords. At 6.5 years, median duration
of response had yet to be reached with both nivolumab-
containing regimens, and only three patients in either group
had experienced PD since the 5-year analysis. Durable
clinical benefit was observed across clinically relevant
subgroups, including those based on baseline BRAF
mutation or baseline liver metastasis status. Less than half
of the patients treated with the combination received any
subsequent therapy, and the median TFI was 27.6 months
with the combination (v 2.3 months with nivolumab and
1.9 months with ipilimumab). Of patients alive at 6.5 years,
77% treated with the combination and 69% treated with
nivolumab were treatment-free. No new safety signals were
observed, no treatment-related deaths had occurred since
the 28-month analysis, and only 11 deaths of any cause
had occurred across the three treatment groups since the
5-year analysis.
Long-term survival analysis in this study continued to show
substantially improved OS with nivolumab alone or in
combination with ipilimumab compared with ipilimumab
alone. Although the study was not powered to compare
nivolumab plus ipilimumab and nivolumab alone, median
OSwith the combination was approximately twice as long as
with nivolumab alone, supporting a meaningful survival
benefit of the combination compared with nivolumab
monotherapy. The durability of the long-term survival
benefit was demonstrated by the continued plateaus of the
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FIG 4. PFS in patients with (A) BRAF-mutant or (B) BRAF–wild-type tumors and OS in patients with (C) BRAF-mutant or (D) BRAF–wild-type tumors.
Patients were followed for a minimum of 77months. In the nivolumab plus ipilimumab, nivolumab, and ipilimumab groups, 314, 316, and 315 patients
had BRAFmutational status results, respectively. aDescriptive analysis. HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free
survival.
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therapiesmay have contributed, in part, to these plateaus, it
is noteworthy that the majority of patients who were alive at
6.5 years were treatment-free in the nivolumab-containing
treatment groups. The 72-month median OS and 49% 6.5-
year OS rate achieved with nivolumab plus ipilimumab
represent an impressive development in the melanoma
treatment landscape when compared with the median OS
of 8 months and 10% 5-year OS rate that was the standard
10 years ago.9 The fact that it is now possible to discrim-
inate between MSS (median not yet reached with nivolu-
mab plus ipilimumab combination therapy) and OS results
further attests to this development. Seven patients across
all three treatment groups experienced PD between the 5-
and 6.5-year analyses. Of 11 deaths since the 5-year
analysis overall, eight resulted from PD and three from
other causes unrelated to treatment. Noting the problems
inherent in cross-trial comparisons, the current results
compare favorably with those obtained with other standard
first-line treatments for advanced melanoma, such as
pembrolizumab, for which a 5-year OS rate of 43.2% has
been reported as first-line treatment.10 Five-year OS rates of
31% to 35% have been reported with the combination of
BRAF and MEK inhibitors in BRAF-mutant melanoma.11-13
With long-term follow-up, the nivolumab-containing regi-
mens in this study continued to demonstrate survival
benefit over ipilimumab alone irrespective of BRAF mu-
tational status. Long-term follow-up also confirmed the
trend of continued separation between the combination
and nivolumab monotherapy curves in patients with BRAF-
mutant disease that has been observed previously,6,7
noting that the study was not designed to formally com-
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Nivolumab Plus
Ipilimumab
(n = 221) 
Nivolumab
(n = 226) 
Ipilimumab
(n = 223) 
Median (95% CI), months 18.1 (10.7 to 42.7) 9.5 (6.7 to 22.3) 3.3 (2.9 to 4.1)
0.37 (0.29 to 0.47) 0.49 (0.39 to 0.61) —HR (95% CI) v ipilimumab
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Nivolumab Plus
Ipilimumab
(n = 221) 
Nivolumab
(n = 226) 
Ipilimumab
(n = 223) 
Median (95% CI), months NR (50.7 to NR) 52.7 (36.0 to NR) 23.5 (18.6 to 29.4)
0.47 (0.37 to 0.60) 0.56 (0.44 to 0.71) —HR (95% CI) v ipilimumab
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Nivolumab Plus
Ipilimumab
(n = 93)  
Nivolumab
(n = 90) 
Ipilimumab
(n = 92) 
Median (95% CI), months 4.4 (2.8 to 11.5) 2.8 (2.7 to 5.4) 2.7 (2.6 to 2.8)
0.55 (0.39 to 0.76) 0.65 (0.47 to 0.90) —HR (95% CI) v ipilimumab
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(n = 90) 
Ipilimumab
(n = 92) 
Median (95% CI), months 28.2 (15.2 to 71.9) 18.2 (8.1 to 32.3) 13.1 (9.6 to 18.4)
0.66 (0.46 to 0.93) 0.81 (0.58 to 1.14) —HR (95% CI) v ipilimumab
0.81 (0.56 to 1.16) — —HR (95% CI) v nivolumab
a
FIG 5. PFS in patients (A) with or (B) without baseline liver metastases and OS in patients (C) with or (D) without baseline liver metastases. Patients were
followed for a minimum of 77 months. aDescriptive analysis. HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival.
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rate of 57% and median OS that had not been reached in
patients with BRAF-mutant disease in the nivolumab plus
ipilimumab group demonstrates the efficacy of this treat-
ment in this patient population and highlights the impor-
tant question of what represents optimal first-line therapy
and treatment sequencing for these patients, a question
that awaits OS results of trials such as SECOMBIT
(NCT02631447) and DREAMseq (NCT02224781) for
more definitive resolution.
In the current analysis, nivolumab-containing regimens,
particularly the combination, also demonstrated long-term
clinical benefit versus ipilimumab in patient subgroups on
the basis of the presence or absence of liver metastases at
baseline. Survival outcomes overall were poorer in patients
with baseline liver metastases than in those without,
confirming the similar observations that have been reported
with pembrolizumab treatment, although the latter were
obtained in a patient population that differed substantially
from that of the current report with respect to a number of
key clinical characteristics.14
With ORRs at 6.5 years that were stable compared with
those reported at 5 years,7 objective responses also
remained durable: median duration of response had yet
to be reached at 77 months’ minimum follow-up with
either nivolumab-containing regimen. Indeed, in the
combination group, patients with objective responses
within the first 12 months of treatment had sustained PFS
and OS, with only three instances of progression noted
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No. at risk:
FIG 6. OS by best overall response in patients in the (A) nivolumab plus ipilimumab, (B) nivolumab, or (C) ipilimumab groups. Patients with a best
overall response of CR, PR, SD, or PD within 12 months of treatment initiation were followed for OS. To address guarantee-time bias, these landmark
analyses excluded patients who had OS events (deaths) during the first 12 months; thus, OS remained at 100% for the first 12 months in this
subpopulation. CR, complete response; OS, overall survival; PD, progressive disease; PR, partial response; SD, stable disease.
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On study therapy Received subsequent systemic therapy Treatment-free (off study treatment and never







Nivolumab Plus Ipilimumab (n = 145)








Nivolumab (n = 122)






Ipilimumab (n = 63)
Median follow-up 81.0 months
(range, 77.0–85.6 months)
FIG 7. Treatment-free interval and treatment status in patients alive at 6.5 years. (A) Median treatment-free interval in each treatment group following
discontinuation of study treatment. Among 313 patients treated with nivolumab plus ipilimumab, 223 were included in the analysis and 90 were
excluded (seven were still on study treatment; 54 had died, six were no longer in follow-up, and six withdrew consent, all without having received
subsequent therapy; 17 were excluded for other reasons). Among 313 patients treated with nivolumab, 237 were included and 76 were excluded
(eight were still on study treatment; 45 had died, two were no longer in follow-up, and three withdrew consent, all without having received subsequent
therapy; 18 were excluded for other reasons). Among 311 patients treated with ipilimumab, 234 patients were included and 77 were excluded (57 had
died, two were no longer in follow-up, and seven withdrew consent, all without having received subsequent therapy; 11 were excluded for other
reasons). Median duration of treatment in these groups is also shown. (B) Treatment status in patients alive at 6.5 years. In the combination group, 145
patients were alive and still in follow-up at 6.5 years and were included in this analysis, and 168 patients were excluded (138 had died, six were lost to
follow-up, seven withdrew consent, and 17 were excluded for other reasons). In the nivolumab group, 122 patients were included and 191 patients
were excluded (164 had died, six were lost to follow-up, three withdrew consent, and 18 were excluded for other reasons). In the ipilimumab group, 63
patients were included and 248 patients were excluded (218 had died, six were lost to follow-up, 13 withdrew consent, and 11 were excluded for other
reasons).
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In this long-term follow-up, the overall safety profile of
the three treatment regimens remained unchanged
since previous reports.4-7 Higher incidences of AEs of all
types were reported with the combination regimen, but
no new safety signals or treatment-related deaths were
observed.
In summary, these 6.5-year data obtained with the com-
bination of first-line nivolumab plus ipilimumab in patients
with advanced melanoma in CheckMate 067 include the
longest median OS reported to date in a phase III mela-
noma study, as well as a median MSS that had not been
reached at 77 months.
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